Repositori URV

Identificador: imarina:9267376

Handle: https://hdl.handle.net/20.500.11797/imarina9267376

Autores:
Rodriguez-Tomas, ElisabetAcosta, Johana C.Torres-Royo, LauraDe Febrer, GabrielBaiges-Gaya, GerardCastane, HelenaJimenez, AndreaVasco, CarlosAraguas, PabloGomez, JuniorMalave, BarbaraArquez, MiguelCalderon, DavidPique, BertaAlgara, ManelMontero, AngelSimo, Josep M.Gabaldo-Barrios, XavierSabater, SebastiaCamps, JordiJoven, JorgeArenas, Meritxell

Resumen:
The aim of our study was to investigate the changes produced by low-dose radiotherapy (LDRT) in the circulating levels of the antioxidant enzyme paraoxonase-1 (PON1) and inflammatory markers in patients with COVID-19 pneumonia treated with LDRT and their interactions with clinical and radiological changes. Data were collected from the IPACOVID prospective clinical trial (NCT04380818). The study included 30 patients treated with a whole-lung dose of 0.5 Gy. Clinical follow-up, as well as PON1-related variables, cytokines, and radiological parameters were analyzed before LDRT, at 24 h, and 1 week after treatment. Twenty-five patients (83.3%) survived 1 week after LDRT. Respiratory function and radiological images improved in survivors. Twenty-four hours after LDRT, PON1 concentration significantly decreased, while transforming growth factor beta 1 (TGF-beta 1) increased with respect to baseline. One week after LDRT, patients had increased PON1 activities and lower PON1 and TGF-beta 1 concentrations compared with 24 h after LDRT, PON1 specific activity increased, lactate dehydrogenase (LDH), and C-reactive protein (CRP) decreased, and CD4+ and CD8+ cells increased after one week. Our results highlight the benefit of LDRT in patients with COVID-19 pneumonia and it might be mediated, at least in part, by an increase in serum PON1 activity at one week and an increase in TGF-beta 1 concentrations at 24 h.